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Summary Post-transplantation lymphoproliferative disorders (PTLDs) are heterogeneous lym-
phoid proliferations representing a major complication of solid organ transplant. PTLDs are
serious complications and may happen at different times after transplantation. Many risk fac-
tors are known, such as age, type of organ transplanted, Epstein—Barr virus (EBV) infectionMediastinal mass;
Re-transplantation
before transplant and immunosuppressive therapy. The PTLD incidence in solid organ trans-
plant recipients is variable: from 1% in patients with renal allografts to 6—10% in patients with
heart—lung transplantation, and up to 20% in lung transplant recipients. Many reports describe
the evolution of PTLDs in heart transplant recipients, but PTLD as an unknown cause of graft
repo
Car
1
t
l
e
t
e
u
Adysfunction has never been
© 2010 Japanese College of
Introduction
Post-transplantation lymphoproliferative disease (PTLD) is
one of the most serious complications of chronic immuno-
suppression in transplant recipients. Involvement of the
cardiac allograft or development of lymphoma in the heart
is extremely rare [1—3].Case report
We present the case of a 57-year-old male, Epstein—Barr
virus (EBV) negative before transplantation, transplanted
∗ Corresponding author at: Division of Cardiac Surgery, Mauriziano
Umberto I Hospital, L.go Turati 62, Turin, Italy.
Tel.: +39 3476653189; fax: +39 0116335509.
E-mail address: fabrisans@katamail.com (F. Sansone).
t
t
d
m
t
p
1
a
a
g
1878-5409/$ — see front matter © 2010 Japanese College of Cardiology.
doi:10.1016/j.jccase.2010.02.003rted.
diology. Published by Elsevier Ireland Ltd. All rights reserved.
year before for ischemic cardiomyopathy. Postopera-
ive course was uneventful and the patient had a regular
ife. Endo-myocardial biopsies (BEM) were negative and the
chocardiographies showed preserved biventricular func-
ion. One year after transplantation, the patient suddenly
xperienced dyspnea and asthenia; he was asymptomatic
ntil 10 days before the hospital admission.
At the beginning, he had effort dyspnea [New York Heart
ssociation (NYHA) II] and peripheral edema. The symp-
oms progressively worsened and the patient was admitted
o the hospital for heart failure (NYHA IV). New echocar-
iography showed biventricular dysfunction with severe
itral and tricuspidal regurgitation, so the patient was
ransferred to our department. Hemodynamics were sup-
orted using high doses of inotropics (dobutamine up to
0 /kg/min and adrenaline up to 0.3 /kg/min) and intra-
ortic balloon pump, inserted through the right femoral
rtery. However, his clinical condition worsened with pro-
ressive reduction of urine output up to anuria requiring
Published by Elsevier Ireland Ltd. All rights reserved.
e F. Sansone, M. Rinaldi
h
c
c
m
C
r
t
t
r
p
p
w
n
C
o
r
b
t
t
t
w
r
i
l
(
(
o
t
a
i
(
i
ﬁ
2
p
p
F
o
a
a
d
t
h
Figure 2 (A) The excised mass (5 cm× 3 cm× 3 cm) that inﬁl-
trated the left atrial appendage. (B) Microscopic appearance.46
emodyalysis. The hypothesis of acute graft rejection was
onsidered but the BEM was negative with normal white cell
ount. Renal and hepatic function were severely compro-
ised with high increase of transaminases and creatinine.
hest radiographies showed pulmonary congestion and pleu-
al effusion without signs of mediastinal masses. Moreover,
ransesophageal echocardiography revealed severe biven-
ricular dysfunction: ejection fraction was about 20% and
ight ventricle was severely dilated and impaired (tricus-
id annular plane systolic excursion—–6mm). Interestingly,
ericardial leaﬂets were normal and no pericardial mass
as detected. Coronary angiography showed normal coro-
ary arteries without signs of chronic allograft rejection.
omputed tomography scan was not performed because
f the instability of the patient. Although acute cellular
ejection was excluded (BEM negative and normal white
lood cell count), the hypothesis of humoral acute rejec-
ion was considered and we used high doses of steroids:
hree doses of prednisone (1 g per dose) were adminis-
ered. However, his clinical condition did not improve, so
e decided to perform re-transplantation. EBV status before
e-transplantation was negative. The intraoperative ﬁnd-
ng was unexpected: we found a mass (5 cm× 3 cm× 3 cm)
ocated behind the main trunk of the pulmonary artery
up to the right ramus) and the left atrial appendage
Fig. 1). The color was prevalent yellow with necrotic areas
f gray. It was not capsulated with hard inﬁltration of
he surrounding tissues; surgical resection was complicated
nd considering that left atrial appendage was completely
nvolved in the neoplastic mass, they were excised together
Fig. 2A). There was no inﬁltration of the coronary arter-
es. The mass was constituted by monomorphic cells with
brotic tissue (Fig. 2B). High resolution image shows CD
0+ cells. Special coloration for mRNA EBER-1 (EBV) was
ositive (Fig. 3A and B). Final diagnosis was B cell lym-
homa with monomorphic population of big cells, EBV
igure 1 The mass [post-transplant lymphoproliferative dis-
rder (PTLD)] located behind the main trunk of the pulmonary
rtery up to the right ramus, involving the left atrial appendage
nd the roof of the left atrium. The mass was detected
uring tissue dissection for removing the heart before re-
ransplantation. The mass was not visible without removing the
eart.
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tigure 3 (A) High resolution image shows CD 20+ cells. (B)
oloration for mRNA EBER-1 (Epstein—Barr virus) was positive.
elated monomorphic post-transplant lymphoproliferative
isorder.
iscussion
TLD includes a large group of lymphoid proliferations
ffecting solid organ and bone marrow transplant recipi-
nts. The wide spectrum of diseases ranges from reactive
ymphoid hyperplasias, borderline proliferations to malig-
ant lymphomas. Incidence of PTLD for each individual type
f transplantation was respectively: 2.6% for heart trans-
lant, 2% for lung/lungs transplant, and 3.3% for heart—lungs
ransplant. Such discrepancy might perhaps be ascribed to a
rogressive improvement in clinical management, as well as
o closer patient follow-up. The main etiological factors of
TLD development are chronic infections, which because of
ermanent antigen stimulation, cause proliferation mainly
f B lymphocytes. At ﬁrst they have a reactive polyclonal
haracter, but in the course of the disease they escape from
he control of suppressor T lymphocytes and the prolifer-
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ation becomes monoclonal and neoplastic. The major risk
factors for PTLD development are type and level of immuno-
suppression and EBV infection status of the host before
transplant. It has been suggested that patients with pre-
transplant EBV negativity have an increased risk of PTLD
and that use of pre-emptive antiviral therapy may reduce
the incidence of EBV-associated PTLD. In fact, our patient
was EBV negative before re-transplantation.
PTLD is the third leading cause of death in cardiac trans-
plant recipients. The classical presentation of the disease
is the appearance of extranodal masses in more than 50%
of patients with PTLD present with extranodal masses [4].
The disease occurs frequently in the gastrointestinal tract,
lungs, skin, liver, and central nervous system, but involve-
ment of the cardiac allograft or development of lymphoma
in the heart is extremely rare [5].
No other report in the literature describes PLTD as a
cause of graft dysfunction and re-transplantation. Our expe-
rience conﬁrms that lymphoproliferative disorders may offer
a large variety of symptoms, very often unrecognized. The
absence of lymphonodal masses and the biventricular dys-
function due to the inﬁltration of the heart, make our case
very unusual.
Computed tomography scanning could offer the possibil-
ity of detecting the mass. However, considering the severe
biventricular dysfunction and the hard inﬁltration of the tis-
sues around the mass (left atrial appendage, roof of the left
atrium, main trunk of the pulmonary artery), surgical resec-
tion without re-transplantation was not possible; moreover,
surgical resection would not ensure recovery of the cardiac
function.Conclusion
In heart transplant recipients, the whole body, including
the transplanted organ, must be aggressively searched for
[e47
TLD, especially if a downhill clinical course cannot be
xplained by either rejection or infection. For this reason,
otal body computed tomography scan should be recom-
ended in order to detect unpredictable masses offering the
ossibility of surgical resection avoiding re-transplantation.
n our case, if PTLD was preoperatively diagnosed, discussion
bout the possibility of re-transplantation would be more
omplicated; ethical questions are already common, but in
he case of graft dysfunction due to PTLD, this could be
contraindication for re-transplantation. In cases such as
his, surgical excision should be the only strategy; if it is
mpossible, we believe that re-transplantation should not
e considered.
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